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A B S T R A C T
Background
Symptoms of anxiety and depression are common in inflammatory bowel disease (IBD). Antidepressants are taken by approximately
30% of people with IBD. However, there are no current guidelines on treating co-morbid anxiety and depression in people with IBD
with antidepressants, nor are there clear data on the role of antidepressants in managing physical symptoms of IBD.
Objectives
The objectives were to assess the efficacy and safety of antidepressants for treating anxiety and depression in IBD, and to assess the
effects of antidepressants on quality of life (QoL) and managing disease activity in IBD.
Search methods
We searched MEDLINE; Embase, CINAHL, PsycINFO, CENTRAL, and the Cochrane IBD Group Specialized Register from
inception to 23 August 2018. Reference lists, trials registers, conference proceedings and grey literature were also searched.
Selection criteria
Randomised controlled trials (RCTs) and observational studies comparing any type of antidepressant to placebo, no treatment or an
active therapy for IBD were included.
Data collection and analysis
Two authors independently screened search results, extracted data and assessed bias using the Cochrane risk of bias tool. We used the
Newcastle-Ottawa Scale to assess quality of observational studies. GRADE was used to evaluate the certainty of the evidence supporting
the outcomes. Primary outcomes included anxiety and depression. Anxiety was assessed using the Hospital Anxiety and Depression
Scale (HADS) or the Hamilton Anxiety Rating Scale (HARS). Depression was assessed using HADS or the Beck Depression Inventory.
Secondary outcomes included adverse events (AEs), serious AEs, withdrawal due to AEs, quality of life (QoL), clinical remission, relapse,
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pain, hospital admissions, surgery, and need for steroid treatment. QoL was assessed using the WHO-QOL-BREF questionnaire. We
calculated the risk ratio (RR) and corresponding 95% confidence intervals (CI) for dichotomous outcomes. For continuous outcomes,
we calculated the mean difference (MD) with 95% CI. A fixed-effect model was used for analysis.
Main results
We included four studies (188 participants). Two studies were double-blind RCTs, one was a non-randomised controlled trial, and
one was an observational retrospective case-matched study. The age of participants ranged from 27 to 37.8 years. In three studies
participants had quiescent IBD and in one study participants had active or quiescent IBD. Participants in one study had co-morbid
anxiety or depression. One study used duloxetine (60 mg daily), one study used fluoxetine (20 mg daily), one study used tianeptine
(36 mg daily), and one study used various antidepressants in clinical ranges. Three studies had placebo controls and one study had a no
treatment control group. One RCT was rated as low risk of bias and the other was rated as high risk of bias (incomplete outcome data).
The non-randomised controlled trial was rated as high risk of bias (random sequence generation, allocation concealment, blinding).
The observational study was rated as high methodological quality, but is still considered to be at high risk of bias given its observational
design.
The effect of antidepressants on anxiety and depression is uncertain. At 12 weeks, the mean anxiety score in antidepressant participants
was 6.11 + 3 compared to 8.5 + 3.45 in placebo participants (MD -2.39, 95% -4.30 to -0.48, 44 participants, low certainty evidence).
At 12 months, the mean anxiety score in antidepressant participants was 3.8 + 2.5 compared to 4.2 + 4.9 in placebo participants (MD -
0.40, 95% -3.47 to 2.67, 26 participants; low certainty evidence). At 12 weeks, the mean depression score in antidepressant participants
was 7.47 + 2.42 compared to 10.5 + 3.57 in placebo participants (MD -3.03, 95% CI -4.83 to -1.23, 44 participants; low certainty
evidence). At 12 months, the mean depression score in antidepressant participants was 2.9 + 2.8 compared to 3.1 + 3.4 in placebo
participants (MD -0.20, 95% -2.62 to 2.22, 26 participants; low certainty evidence).
The effect of antidepressants on AEs is uncertain. Fifty-seven per cent (8/14) of antidepressant participants group reported AEs versus
25% (3/12) of placebo participants (RR 2.29, 95% CI 0.78 to 6.73, low certainty evidence). Commonly reported AEs include nausea,
headache, dizziness, drowsiness, sexual problems, insomnia, fatigue, low mood/anxiety, dry mouth, muscle spasms and hot flushes.
None of the included studies reported any serious AEs. None of the included studies reported on pain.
One study (44 participants) reported on QoL at 12 weeks and another study (26 participants) reported on QoL at 12 months. Physical,
Psychological, Social and Environmental QoL were improved at 12 weeks compared to placebo (all low certainty evidence). There
were no group differences in QoL at 12 months (all low certainty evidence). The effect of antidepressants on maintenance of clinical
remission and endoscopic relapse is uncertain. At 12months, 64% (9/14) of participants in the antidepressant groupmaintained clinical
remission compared to 67% (8/12) of placebo participants (RR 0.96, 95% CI 0.55 to 1.69; low certainty evidence). At 12 months,
none (0/30) of participants in the antidepressant group had endoscopic relapse compared to 10% (3/30) of placebo participants (RR
0.14, 95% CI 0.01 to 2.65; very low certainty evidence).
Authors’ conclusions
The results for the outcomes assessed in this review are uncertain and no firm conclusions regarding the efficacy and safety of antide-
pressants in IBD can be drawn. Future studies should employ RCT designs, with a longer follow-up and develop solutions to address
attrition. Inclusion of objective markers of disease activity is strongly recommended as is testing antidepressants from different classes,
as at present it is unclear if any antidepressant (or class thereof ) has differential efficacy.
P L A I N L A N G U A G E S U M M A R Y
Antidepressants for inflammatory bowel disease
What is inflammatory bowel disease?
Inflammatory bowel disease (IBD) is a chronic, inflammatory disease affecting the gastrointestinal tract (colon or small intestine or
both). IBD predominantly comprises Crohn’s disease and ulcerative colitis. Symptoms of IBD include diarrhoea, urgency of defecation
(including faecal incontinence), abdominal pain, rectal bleeding, fatigue and weight loss. When people experience symptoms of IBD
they are considered to have active disease. When symptoms of IBD stop the disease is in remission. IBD is associated with a psycho-
social burden, with rates of depression in people with IBD twice as high as in the general population. Anxiety and depression which
accompany IBD may be associated with poor quality of life, worsening IBD activity, higher hospitalisation rates and lower adherence to
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treatment. Up to 30% of people living with IBD take antidepressants which are prescribed for either mental health or bowel symptoms
or both.
What are antidepressants?
Antidepressants are drugs used to treat depression and other mental disorders such as anxiety. No antidepressants are currently approved
by regulatory agencies for specifically treating anxiety and depression, to manage physical symptoms or to reduce bowel inflammation in
people with IBD. However, some antidepressants have indications for treatment of pain in chronic conditions and have been commonly
used to manage functional bowel symptoms in conditions such as irritable bowel syndrome.
What did the researchers investigate?
Previously conducted studies of antidepressant therapy in IBD were reviewed. The data from some of these studies were combined
using a method called a meta-analysis. During the analysis, people who took antidepressants were compared with those who did not
take antidepressants with regard to rates of anxiety and depression and also other measures such as quality of life, side effects and IBD
disease activity.
What did the researchers find?
The researchers searched the medical literature up to 23 August 2018. Four published studies, including a total of 188 people, examined
antidepressant therapy in people with IBD. The age of participants ranged from 27 to 37.8 years. In three studies participants had IBD
in remission and in one study participants had either active IBD or IBD in remission. Participants in one study had co-existing anxiety
or depression. One study used duloxetine (60 mg daily), one study used fluoxetine (20 mg daily), one study used tianeptine (36 mg
daily), and one study used various antidepressants. Three studies had a placebo (e.g. sugar pill) control group and one study had a no
treatment control group.
The analysis showed that the symptoms of anxiety and depression were improved in those who took antidepressants compared to
placebo. Participants who received antidepressants experienced more side effects than those who received placebo. Side effects reported
by those taking antidepressants included: nausea, headache, dizziness, drowsiness, sexual problems, insomnia, fatigue, low mood/
anxiety, dry mouth, poor sleep, restless legs and hot flushes. Some aspects of quality of life were improved as was IBD activity in the
antidepressant group. The overall quality of the studies included in this review was poor because the studies included small numbers
of participants, and involved IBD populations which differed from each other on key characteristics. In addition, different types of
antidepressants were assessed so the evidence for any one antidepressant was uncertain. Therefore, future studies are needed to confirm
these observations.
Conclusion
The results for the outcomes assessed in this review are uncertain and no firm conclusions regarding the benefits and harms of
antidepressants in IBD can be drawn. More studies are needed to allow for firm conclusions regarding the benefits and harms of the
use of antidepressants in people with IBD.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antidepressants compared to placebo for inflammatory bowel disease
Patient or population: part icipants with act ive and inact ive inf lammatory bowel disease
Setting: Outpat ient
Intervention: Antidepressants
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with Placebo Risk with Antidepres-
sants
Anxiety at 12 weeks The mean anxiety was
8.5 (SD = 3.45)
The mean anxiety was
6.11 (SD = 3)
MD 2.39 lower
(-4.3 lower to -0.48
higher)
- 44
(1 study)
⊕⊕©©
low1,2
Anxiety was assessed
using the HADS
Anxiety at 12 months The mean anxiety was
4.2 (SD = 4.9)
The mean anxiety was
3.8 (SD = 2.5)
MD -0.40 lower
(-3.47 lower to 2.67
higher)
- 26
(1 study)
⊕⊕©©
low3
Anxiety was assessed
using the HADS
A second non-ran-
domised study using
the HARS reported a
mean score of 12.65
+ 3.76 in the ant ide-
pressant group (n = 30)
compared to 17.85 + 3.
33 in the placebo group
(n = 30) (MD -5.20, 95%
CI -7 to -3.40; very low
certainty evidence)
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Depression at 12 weeks The mean depression
was 10.5 (SD = 3.57)
The mean depression
was 7.47 (SD = 2.42)
MD -3.03 lower
(-4.83 lower to -1.23
higher)
- 44
(1 study)
⊕⊕©©
low1,2
Depression was as-
sessed using the HADS
Depression at 12
months
The mean depression
was 3.1 (SD = 3.4)
The mean depression
was 2.9 (SD = 2.8)
MD -0.20 lower
(-2.62 lower to 2.22
higher)
- 26
(1 study)
⊕⊕©©
low3
Depression was as-
sessed using the HADS
A second non-ran-
domised study using
the Beck Depression
Inventory reported a
mean score of 9.6 +
2.76 in the ant idepres-
sant group (n = 30)
compared to 16.35 + 5.
41 in the placebo group
(n = 30) (MD -6.75, 95%
CI -8.92 to -4.58; very
low certainty evidence)
Adverse events at 12
months
250 per 1,000 573 per 1,000
(195 to 1,000)
RR 2.29
(0.78 to 6.73)
26
(1 study)
⊕⊕©©
low4
Commonly reported ad-
verse events include
nau-
sea, headache, dizzi-
ness, drowsiness, sex-
ual problems, insomnia,
fat igue, low mood/ anx-
iety, dry mouth muscle
spasms and hot f lushes
None of the included
studies reported any se-
rious adverse events
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Quality of lif e - - See comment 70
(2 studies)
⊕⊕©©
low1,2,3
Quality of lif e was as-
sessed using the WHO-
QOL-BREF
We were unable to
pool data as the out-
come was reported at
12 weeks in 1 trial
(44 part icipants) and
12 months in 1 trial
(26 part icipants). Phys-
ical, Psychological, So-
cial and Environmental
QoL were improved only
at 12 weeks with no
group dif ference at 12
months
Pain Not reported No studies reported
this outcome
Maintenance of remis-
sion at 12 months
667 per 1,000 640 per 1,000
(367 to 1,000)
RR 0.96
(0.55 to 1.69)
26
(1 study)
⊕⊕©©
low5
Maintenance of remis-
sion was measured by
the CDAI (< 150) and fe-
cal calprotect in levels
Endoscopic relapse at
12 months
0 per 1,000 0 per 1,000
(0 to 0)
RR 0.14
(0.01 to 2.65)
60
(1 study)
⊕©©©
very low6
Non-randomised study.
We were unable to
calculate absolute ef -
fects. Endoscopic re-
lapse occurred in 0%
(0/ 30) of part icipants
in the ant idepressants
group compared to 10%
(3/ 30) in the placebo
group
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; CMD: Common mental disorders; MD: Mean Dif ference; HADS: Hospital Anxiety and Depression Scale; HARS: Hamilton Anxiety Rating Scale; RR: Risk
Ratio;WHO-QOL-BREF: World Health Organizat ion Quality of Life abbreviated quest ionnaire
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious imprecision (44 part icipants)
2 Downgraded one level due to high risk of bias (incomplete outcome data)
3 Downgraded two levels due very serious imprecision (26 part icipants)
4 Downgraded two levels due very serious imprecision (11 events)
5 Downgraded two levels due very serious imprecision (17 events).
6 Downgraded one level due to very serious imprecision (3 events) and a large CI around the point est imate
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B A C K G R O U N D
Description of the condition
Inflammatory bowel disease (IBD) is a chronic, inflammatory dis-
ease affecting the gastrointestinal tract. The aetiology of IBD is
thought to involve an inappropriate immune response to intestinal
microbiota, triggered by environmental factors, in genetically sus-
ceptible people. The typical symptoms of IBD include diarrhoea,
urgency of defecation, abdominal pain and cramping, fatigue, and
weight loss. IBD affects 2.2 million people in Europe (Loftus
2004), 1.4 million people in the USA (CCFA 2012), 233,000
people in Canada (Rocchi 2012), and over 75,000 people in Aus-
tralia (CCA 2015).
IBD is associated with a psychosocial burden. People with IBD
have a higher life-time prevalence of depression compared to the
general community, with estimated rates of 27% in persons with
IBD compared to 12% in the general population (Walker 2008).
During IBD remission, over 20% of people report symptoms of
anxiety or depression but this number rises to 60% when IBD
is active (Mikocka-Walus 2016a). Psychological stress has been
found to predict symptomatic disease course (Bernstein 2011),
and is also linked to increased inflammation (Maunder 2008).
Associations between symptoms of depression and clinical recur-
rence over time (Mikocka-Walus 2016d), higher hospitalisation
rates (Van Langenberg 2010), and lower adherence to treatment
(Nigro 2001), have also been suggested.
Despite the high prevalence of mental co-morbidities with IBD
and the effect on disease course, mental disorders are not rou-
tinely treated in this population. In fact, fewer than 40% of
those with IBD reporting mental symptoms receive psychother-
apy (Bennebroek Evertsz 2012). Poor access to psychologists may
contribute to this finding. In the UK, for example, only a frac-
tion of IBD services (12%) have access to clinical psychology
(RCP 2014). However, psychotherapy is not a universal treatment
for mental and physical symptoms associated with IBD (Timmer
2011). While the most recent meta-analysis demonstrated that
psychological therapies, and cognitive behavioural therapy in par-
ticular, might have small short-term beneficial effects on depres-
sion scores and quality of life (QoL) in IBD (Gracie 2017), there
is no evidence that psychotherapies are effective for IBD activity.
The limitations of the current studies on psychotherapy in IBD
are discussed elsewhere (Knowles 2013).
Depending on the population, 10% to 30% of IBD patients
take antidepressants (Fuller-Thomson 2006; Haapamaki 2013;
Mikocka-Walus 2012). However, studies have shown that those
IBD patients who receive antidepressants do not necessarily suffer
from depression but often are treated for pain, insomnia or func-
tional bowel symptoms which overlap with IBD (Mikocka-Walus
2007; Mikocka-Walus 2012). This resembles treatment for func-
tional gut disorders such as irritable bowel syndrome, where there
is good evidence of antidepressants’ efficacy for physical symptoms
(Ford 2009; Ford 2014). However, while antidepressants are used
in IBD, the efficacy of this intervention in this population has not
been established to date.
Description of the intervention
Antidepressants are drugs used to treat depression and other men-
tal disorders such as anxiety. While lithium was known in the 19th
century, it wasn’t introduced to common psychiatry practice until
the 1950s (Shorter 2009). Other antidepressants - monoamine
oxidase inhibitors and tricyclics were also introduced in the 1950s
while tetracyclics were introduced in the 1970s. Presently, the
most commonly used antidepressants are selective serotonin reup-
take inhibitors (SSRIs) which were introduced in the 1980s. Sero-
tonin-norepinephrine reuptake inhibitors (SNRIs) became avail-
able in the 1990s. Other less commonly known groups of an-
tidepressants include: heterocyclics, norepinephrine reuptake in-
hibitors (NARIs), norepinephrine-dopamine reuptake inhibitors
(NDRIs), noradrenergic and specific serotonergic antidepressants
(NaASSAs), and serotonin antagonist and reuptake inhibitors
(SARIs).
Dosage regimens differ between the different classes and individ-
ual antidepressants, and depend on the severity of symptoms. An-
tidepressants are usually taken daily (either morning or night) and
the treatment ranges from several months to several years or even
lifetime use. The efficacy of older antidepressants (e.g. tricyclics)
andnewer, second-generation antidepressants (e.g. SSRI) is similar
(Williams 2000). However, the use of first generation antidepres-
sants is associated with more serious adverse events, with increased
lethality with overdose (Gartlehner 2007; Gartlehner 2011), and
thus these agents are no longer first line pharmacotherapy treat-
ment for depression or anxiety. Among the new generation antide-
pressants, escitalopram and sertraline are considered to be superior
to other commonly used antidepressants in terms of efficacy and
acceptability (Cipriani 2009).
No antidepressants are currently approved by regulatory agen-
cies for specifically treating anxiety and depression comorbid with
IBD, to manage physical symptoms of IBD or to reduce bowel in-
flammation. However, some antidepressants have indications for
treatment of pain in chronic conditions. For example, duloxetine
has an indication for diabetic peripheral neuropathy (AMH 2012).
How the intervention might work
Antidepressants are thought to work through compensating for
transmitter deficits in the brain, which are considered to be the
underlying cause of depression (Ritter 2015). Antidepressants can
either inhibit the reuptake of neurotransmitters from the synaptic
cleft or inhibit the metabolism of neurotransmitters. Thus, for ex-
ample, tricyclics inhibit the uptake of noradrenaline or serotonin
or both. SSRIs inhibit serotonin uptake, while SNRIs inhibit both
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noradrenaline and serotonin uptake, and monoamine oxidase in-
hibitors inhibit themetabolism of mono-amine neurotransmitters
such as serotonin. However, it is also hypothesized that antidepres-
sants may help treat depression due to immunoregulatory effects
(Maes 2001). A significant drop in serum C-reactive protein con-
centrations (independent of depressive symptoms being resolved)
has been observed following four weeks of treatment with SSRIs
in people with a major depressive disorder (O’Brien 2006). Even
in healthy volunteers, antidepressants have been shown to im-
prove immunoregulatory activity (Szuster-Ciesielska 2003); and
in sufferers of chronic inflammatory conditions such as asthma,
antidepressants are reported to reduce the need for steroids (Brown
2005), and improve overall immune function (Krommydas 2005).
Given the immunoregulatory effect of antidepressants, it is pos-
sible that when given to patients with inflammatory conditions
such as IBD, antidepressants may exert an effect on inflamma-
tion outside the brain and thus improve not only mood but also
bowel symptoms, by extending or inducing remission. Animal
studies examining models of colitis can serve as a proof of concept
(Mikocka-Walus 2009). For example, mice receiving desipramine
(a tricyclic antidepressant) have significantly reduced microscopic
damage (P < 0.05) and attenuation of colonic myeloperoxidase
activity (P < 0.05) when compared to placebo (Varghese 2006).
Furthermore, serum Il-1β concentrations were significantly lower
in rats receiving 10 mg fluoxetine (an SSRI), 20 mg fluoxetine,
20 mg desipramine or 10 mg desipramine compared to controls
(all P < 0.001) (Guemei 2008). Similarly, reductions in serum tu-
mour necrosis factor-alpha were observed in rats receiving either
desipramine or fluoxetine (10 or 20 mg) compared to controls (all
P < 0.001). Thus, antidepressants can induce an anti-inflamma-
tory response which is not related to antidepressive effects.
Further, treatments which improve inflammation in IBD, such as
biologics, are known to also improve QoL (Feagan 2007). Thus,
it is hypothesised that antidepressants can reduce symptoms of
anxiety and depression and improve QoL in IBD. It is further hy-
pothesised that, similarly to what occurs in animal models where
antidepressants have been shown to have anti-inflammatory prop-
erties, antidepressants may induce remission of IBD and reduce
the number of flares in humans.
Why it is important to do this review
There is a growing interest in mental health and antidepressant use
in chronic illness, to manage comorbid depression as well as physi-
cal symptoms, with recentCochrane systematic reviews conducted
on diabetes (Baumeister 2014), coronary artery disease (CAD)
(Baumeister 2011), and functional gut disorders (Ruepert 2011).
These reviews have shown improved glycaemic control after the
use of SSRIs versus placebo in patients with diabetes (Baumeister
2014); improvements in depression, reduction in hospitalisations
and emergency room visits (though no beneficial effects on mor-
tality, cardiac events or QoL) after SSRI use compared to placebo
in CAD (Baumeister 2011); and improvements in abdominal pain
and symptoms (after tricyclics as compared to placebo) and in
global assessment (after SSRIs as compared to placebo) in irritable
bowel syndrome (Ruepert 2011). However, there is currently no
Cochrane systematic review exploring the role of antidepressants
in IBD.
The first systematic review on the use of antidepressants in IBD
was conducted in 2005 and identified 12 uncontrolled studies
(Mikocka-Walus 2006). While the review observed a beneficial
effect of antidepressants on mental and physical status of IBD pa-
tients, the available research was of low quality, making it impossi-
ble to provide definitive conclusions on the efficacy of antidepres-
sants for improving outcomes in patients with IBD. Amore recent
systematic review (Macer 2017), included 15 studies including 1
randomised controlled trial, 2 cohort studies, 1 case-control study,
1 cross-sectional survey, 1 qualitative study, 2 audits, 1 case se-
ries, and 6 case reports. Twelve studies suggested that antidepres-
sants have a positive impact on IBD course. Nine studies reported
on anxiety and depression as outcomes. Eight of these studies re-
ported beneficial effects of antidepressants. Most of the studies
were deemed to be at low risk of bias, apart from the case reports,
which were at high risk of bias. While this review confirmed the
beneficial effect of antidepressants on IBD course, it concluded
that it was not possible to determine efficacy of antidepressants
for certain due to the lack of randomised controlled trials (RCTs).
Since the publication of the latest review another trial of antide-
pressant use in IBD has been published (Mikocka-Walus 2017).
It is now time to review current evidence on the effectiveness and
safety of antidepressants for mood and disease activity in IBD pa-
tients. It is also critical to conduct the first meta-analysis of the
effects of antidepressants in IBD management.
Given the widespread use of antidepressants in IBD (Fuller-
Thomson 2006; Haapamaki 2013; Mikocka-Walus 2012), and
the potential for not only addressing poor mental health but also
immunoregulatory activity (Krommydas 2005), it is important to
assess the efficacy and safety of antidepressants in IBD. This re-
view explores the adjuvant role of antidepressants in IBD.
O B J E C T I V E S
Primary objectives
• To assess the efficacy and safety of antidepressants for
treating anxiety and depression in IBD.
Secondary objectives
• To assess the efficacy and safety of antidepressants for
improving QoL in IBD.
• To assess the efficacy and safety of antidepressants for
managing IBD disease activity.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished quantitative studies including:
RCTs, and non-randomised controlled studies, prospective and
retrospective studies including cohort, case control, cross-sectional
and audit studies, were eligible for inclusion. Studies without a
comparison group were excluded.
Types of participants
Humans, clinically diagnosed with IBD of any type (i.e. Crohn’s
disease, ulcerative colitis or indeterminate colitis) - according to
standard practice (i.e. a combination of clinical, radiologic, endo-
scopic and histologic grounds), were considered for inclusion.
Types of interventions
All types of antidepressants (in any dose) were included:
• SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine,
paroxetine, sertraline);
• Tricyclics (amitriptyline, clomipramine, desipramine,
dothiepin, doxepin, imipramine, lofepramine, nortriptyline,
protriptyline, trimipramine);
• Heterocyclics (mianserin);
• MAO inhibitors (isocarboxazid, phenelzine,
tranylcypromine, brofaromine, moclobemide, tyrima);
• NARIs (reboxetine);
• NDRIs (amineptine, buproprion);
• SNRIs (duloxetine, milnacipran, venlafaxine);
• NASSAs (mirtazapine);
• SARIs (trazodone); and
• Other unclassified antidepressants (agomelatine,
vilazodone).
Any comparator including any of the following was considered for
inclusion:
• No intervention;
• Placebo;
• Standard care/treatment as usual;
• Surgery;
• Alternative interventions used to treat depression and
anxiety, e.g. anxiolytics, psychotherapy;
• Another antidepressant; and
• Any other active comparators.
Types of outcome measures
Primary outcomes
Efficacy
• Anxiety and depression as measured by any well-established
anxiety or depression scale
Secondary outcomes
Safety
• Adverse events;
• Serious adverse events;
• Study withdrawal due to adverse events.
Efficacy
• QoL as measured by any well-established QoL scale;
• IBD clinical remission or relapse;
• Pain severity as established using any well-established pain
scale; and
• Hospital admissions, surgery, need for steroid treatment.
Search methods for identification of studies
Electronic searches
The following sources were searched from inception to 23rd Au-
gust 2018 and without language restrictions:
• MEDLINE via PubMed (Appendix 1);
• Embase (Appendix 2);
• CINAHL (Appendix 3);
• PsycINFO (Appendix 4);
• CENTRAL; and
• The Cochrane IBD Group Specialized Register.
Trial registries were searched to identify any unpublished or on-
going studies. These registries included:
• The WHO Trials portal (ICTRP);
• ClinicalTrials.gov; and
• The EU clinical trials register.
Conference proceedings were searched to identify studies pub-
lished in abstract form. These conferences included:
• Digestive Disease Week;
• United European Gastroenterology Week;
• European Crohn’s and Colitis Organisation; and
• Advances in IBD.
The grey literature database Open Grey was searched to identify
studies not indexed in the major databases.
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Searching other resources
We searched the reference lists of included studies and applica-
ble systematic reviews to identify studies missed by the database
searches.
Data collection and analysis
Selection of studies
Two authors (AMW, JP) independently screened titles and ab-
stracts identified by the search and excluded those studies not
meeting the selection criteria. Full text reports were obtained for
all the studies deemed eligible and were read independently by
two review authors (AMW, JP). For the studies co-authored by
AMW, eligibility was assessed by other researchers (JP, SLP). If in-
formation pertaining to eligibility was missing, we contacted the
authors of the studies for further information. In cases where the
two authors could not reach consensus on study eligibility, a third
investigator (SLP or SK) was consulted.
Data extraction and management
Data were independently extracted by two authors (AMW, JP or
JP and SLP in the case of the trial co-authored by AMW). Any
disagreements were resolved by consensus and, if this could not
be reached, a third author (SLP or SK) was asked to arbitrate.
The following information was extracted:
• General study information: authors, year, country;
• Method: design (including details such as: randomisation,
allocation concealment, duration, follow-up), setting,
recruitment, intervention (type of antidepressant, dose,
frequency, type of controls, adherence), clinical measures (e.g.
disease activity measure, measures of anxiety/depression), sample
size calculation;
• Participants: number of participants, age, sex, IBD type, per
cent in remission; and
• Outcomes: descriptives (mean/SD or median/inter-quartile
range (or range), frequency (%) plus accompanying statistics, e.g.
OR, P value) for primary and secondary outcome measures at
time points, adverse events, and loss to follow-up.
We contacted the authors of one study about missing or unclear
information and the study authors provided the requested data
(Chojnacki 2011).
Assessment of risk of bias in included studies
Two authors independently assessed the risk of bias. The variety
of study designs included in this review necessitated the use of
several different quality assessment tools. For RCTs, the Cochrane
risk of bias tool was used (Higgins 2011). The following types
of bias were examined: selection bias (sequence generation and
allocation sequence concealment, two items), performance bias
(blinding of participants and personnel, two items), detection bias
(blinding of outcome assessment, one item), attrition bias (incom-
plete outcome data at short-term (two to six weeks) and at long-
term (greater than six weeks, two items), reporting bias (selective
outcome reporting, one item). Each item was rated as either ‘Low
risk’, ‘High risk’ or ’Unclear risk’. For observational studies (case-
control), we used the Newcastle-Ottawa Scale (Wells 2000), for
which a study could score a possible of nine points, with a higher
score consistent with better methodological quality.
In addition, the GRADE approach was used to evaluate the
overall quality of the evidence supporting the primary outcomes
and selected secondary outcomes (Guyatt 2008). Following the
GRADE, evidence from randomised trials starts as high quality but
may be downgraded due to within-study risk of bias (methodolog-
ical quality), indirect evidence, unexplained heterogeneity, impre-
cision of effect estimates and risk of publication bias. Evidence
from non-randomised studies starts as low quality. Each outcome
was assigned one of the following scores: high quality (future re-
search unlikely to change confidence in the estimate); moderate
quality (future research likely to impact confidence in the esti-
mate); low quality (future research very likely to impact confidence
in the estimate); very low quality (the estimate is uncertain).
Summary of findings tables were prepared for the following out-
comes post-treatment:
• Anxiety symptoms;
• Depression symptoms;
• Adverse events;
• Quality of life;
• Pain;
• Clinical remission; and
• Relapse.
Measures of treatment effect
We used the RevMan software for data analysis. For dichotomous
outcomes, we calculated the risk ratio (RR) and corresponding
95%confidence interval (CI). The number needed to treat (NNT)
and risk difference (RD) were calculated where appropriate. For
continuous outcomes, the mean difference (MD) or standardised
mean difference (SMD) and corresponding 95% CI were calcu-
lated.
Unit of analysis issues
Where the efficacy of multiple antidepressants (on IBD activity)
was meant to be compared, it was planned to split the shared com-
parison group (e.g. standard care or psychotherapy) equally be-
tween the antidepressants arms as comparison groups. However,
such a study was not identified. Cross-over trials were to be in-
cluded only when antidepressant and comparator data were ex-
tracted from the first treatment period or when the sufficient wash-
out period occurred between treatment periods (e.g. two weeks
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for all antidepressants except for fluoxetine where four weeks are
required in light of the long plasma half-life). However, no cross-
over trial was identified. SE was converted into SD using the fol-
lowing formula: SD = SE /
√
1/NE+1/NC .
Dealing with missing data
Where possible, the intention-to-treat principle was adhered to.
In the case of dichotomous data when treatment response was
compared, the total number of participants in each pre-treatment
comparison group (as the denominator) was included. In the anal-
yses of treatment response, only the data from studies reporting
a group size prior to drop-outs were included. For continuous
outcome measures, we included summary statistics derived from
(in order of preference) mixed-effects models, observed cases sum-
mary statistics, and last observation carried forward where pos-
sible. This was dictated by the notion that mixed-effects models
are considered less biased than the analyses of the last observation
carried forward (Verbeke 2000).
Assessment of heterogeneity
We planned to assess clinical homogeneity using the forest plot
of the risk ratio. We also planned to review the results of the Chi
2 test. A P value of less than 0.10 was to be considered evidence
of statistically significant heterogeneity (assuming the low power
of the Chi2 statistic when few trials are available) (Deeks 2011).
This proved impractical due to the very small number of studies
identified.
The I2 statistic was used to assess heterogeneity across trials
(Higgins 2003). An I2 statistic greater than 30% was considered
moderate heterogeneity and greater than 50% was considered se-
vere heterogeneity.
Subgroup differences in continuous measures of antidepressant ef-
ficacy were to be investigated using Deeks’ stratified test of het-
erogeneity (Deeks 2001). Herein the sum of the Chi2 statistics for
each of the subgroups included in the study is subtracted from the
Chi2 statistic for all the studies, to provide a measure (Qb) of het-
erogeneity between groups. As different antidepressants may exert
different effects, we planned to stratify all of the outcome compar-
isons by the individual antidepressant used (excluding subgroup
and sensitivity analyses). This however proved impossible due to
each study using a different type of antidepressant.
Assessment of reporting biases
Small-sample effects were to be investigated by visual inspection of
a funnel plot of treatment response (Sterne 2011). This was how-
ever deemed inappropriate as we identified fewer than 10 studies
and the method is not robust in such cases (Egger 1997).
Data synthesis
The pooled RR and corresponding 95% CI was calculated for di-
chotomous outcomes. For continuous outcomes, the pooled MD
or SMDwith 95%CIwas calculated as appropriate. It was planned
to combine dichotomous and continuous variables using the stan-
dardCochrane procedure (InOR=SMDXπ /
√
3) (Deeks 2011),
but this proved unnecessary. We obtained categorical and contin-
uous treatment effects using a fixed-effect model. The outcomes
were expressed as an average effect size for each subgroup and
95% CIs. In some models, heterogeneity was present and in such
cases random-effects models are usually preferred. However, the
Cochrane Handbook does warn that if the effect size is associated
with sample size, then using a random-effects model will award
relatively more weight to the smaller studies, and will exacerbate
bias (Deeks 2011). This is further confirmed by a recent evidence
synthesis (Bender 2018). As this review includes a small number
of studies, a fixed-effect model was applied for the analyses.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was to be conducted for the following sub-
groups:
IBD subtype: Crohn’s disease versus ulcerative colitis or indeter-
minate colitis;
Sex: Male versus female; and
Types of antidepressants: SSRI versus tricyclics.
This was not deemed practical due to the small number of studies.
Sensitivity analysis
Sensitivity analysis was to be performed to check the robustness
of our conclusions for the meta-analysis of the primary outcome.
We planned to follow the same procedure as was applied in our
previous protocol on a similar topic (Gordon 2013):
We planned to assess whether treatment response varies as a func-
tion of the use of treatment response versus non-response as out-
comes. Treatment response may produce less consistent outcome
statistics than non-response in cases when the control group event
rate is greater than 50% (Deeks 2002). This analysis was only to
be conducted if the majority of studies reported a control group
event rate greater than 50%. This was not the case for the analysis.
Conducting a ’worst case/best case’ analysis was considered to
examine the impact of the exclusion of those lost to follow-up on
treatment efficacy effect estimates (Deeks 2011). Herein, for the
worst case scenario, all the missing data for the treatment group
were to be recorded as non-responders. For the best case scenario,
all missing data in the control group were to be considered non-
responders. Where the effect estimates of treatment efficacy would
not differ between these two comparisons, it would be concluded
that missing data in the studies did not have a marked impact on
outcomes. This analysis was to be done in case we had access to
full data sets for the included studies. This was the case for one
study only (Mikocka-Walus 2016c).
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R E S U L T S
Description of studies
Results of the search
The search was conducted on 23 August 2018 and identified
3920 records. After duplicates were removed, 3144 records were
screened for inclusion. Of the studies that were screened, 16 were
selected for full text review. Overall, 4 studies met the inclusion
criteria (Figure 1). No additional studies were identified through
other sources.
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Figure 1. Study flow diagram.
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Included studies
Country
Included studies came from four countries: one each conducted
in Australia (Mikocka-Walus 2016c), Iran (Daghaghzadeh 2015),
Poland (Chojnacki 2011) and the United Kingdom (Goodhand
2012).
Study design
The search identified two double blind RCTs (Daghaghzadeh
2015; Mikocka-Walus 2016c), one non-randomised controlled
trial (Chojnacki 2011), and one observational retrospective case-
matched study (Goodhand 2012).
Participant characteristics
The studies included a total of 188 patients with IBD (96 as-
signed to intervention and 93 assigned to controls). The age
of participants ranged from 27 (Goodhand 2012) to 37.8 years
(Daghaghzadeh 2015). The proportion of female participants
ranged from 46% (Daghaghzadeh 2015; Mikocka-Walus 2016c)
to 65% (Chojnacki 2011). In three studies participants were in
IBD remission (Chojnacki 2011; Daghaghzadeh 2015; Mikocka-
Walus 2016c) and in one study participants had mixed IBD activ-
ity (Goodhand 2012). In one study participants had to have co-
morbid symptoms of anxiety and/or depression (Chojnacki 2011)
while in the remaining studies this was not part of the inclu-
sion criteria. Two studies included both participants with Crohn’s
disease and ulcerative colitis (Daghaghzadeh 2015; Goodhand
2012), one study included only participants with Crohn’s disease
(Mikocka-Walus 2016c) and another only those with ulcerative
colitis (Chojnacki 2011).
Treatment
In the experimental groups, one study used duloxetine 60mg daily
(an SNRI antidepressant) (Daghaghzadeh 2015), one study used
fluoxetine 20 mg daily (an SSRI antidepressant) (Mikocka-Walus
2016c), one study used tianeptine 12 mg three times a day (an
atypical antidepressant) (Chojnacki 2011), and one study used
various antidepressants in clinical ranges (Goodhand 2012). Three
studies used a placebo control (Chojnacki 2011; Daghaghzadeh
2015; Mikocka-Walus 2016c), and one study used a no treatment
control group matched for various clinical and demographic char-
acteristics (Goodhand 2012).
Follow-up
The follow-up periods ranged from 12 weeks to 12 months, with
one study (Goodhand 2012) observing participants 12 months
before and 12 months after being prescribed an antidepressant. In
two studies no attritionwas recorded (Chojnacki 2011;Goodhand
2012), while in one study 79% of participants remained in the
study at 12-weeks of follow-up (Daghaghzadeh 2015), and in an-
other study 69% of participants remained in the study at 12-
months of follow-up (Mikocka-Walus 2016c).
Outcome measures
In terms of the primary outcome measures, three studies mea-
sured symptoms of anxiety and depression (Chojnacki 2011;
Daghaghzadeh 2015; Mikocka-Walus 2016c). Symptoms of anxi-
ety and depression were measured using the Hospital Anxiety and
Depression Scale (HADS) in two studies (Daghaghzadeh 2015;
Mikocka-Walus 2016c), and the Hamilton Anxiety Rating Scale
(HARS) and the Beck Depression Inventory (BDI) in one study
(Chojnacki 2011).
Regarding the secondary outcome measures, three studies mea-
sured adverse events (Chojnacki 2011; Daghaghzadeh 2015;
Mikocka-Walus 2016c), two studies measured study with-
drawal due to adverse events and QoL (Mikocka-Walus
2016c; Daghaghzadeh 2015). All studies measured IBD activ-
ity. Three studies used an IBD activity index (Chojnacki 2011;
Daghaghzadeh 2015; Mikocka-Walus 2016c), two studies used
blood tests ( Chojnacki 2011; Mikocka-Walus 2016c), one study
used faecal calprotectin (Mikocka-Walus 2016c), and one study
used endoscopy (Chojnacki 2011).
QoL was measured using theWorld Health Organization Quality
of Life (WHOQOL-BREF) questionnaire (Daghaghzadeh 2015;
Mikocka-Walus 2016c). The WHOQOL-BREF is a short ver-
sion of the World Health Organization Quality of Life (WHO-
QOL-100) questionnaire and is a tool which can be used cross-
culturally to evaluate quality of life (WHOQOL-BREF). WHO-
QOL-BREF measures four major domains of QoL: physical (cor-
responding with physical health, e.g. fatigue, pain, sleep), psycho-
logical (corresponding with psychological well-being, e.g. self-es-
teem, body image, positive or negative feelings), social relation-
ships (corresponding with personal relationships, social support
and sexual functioning) and environment (corresponding with
people’s relationship to their environment, e.g. safety, financial re-
sources, transport, physical environment).
Disease activity indices included the Crohn’s Disease Activity In-
dex (CDAI) (Mikocka-Walus 2016c), the Lichtiger Colitis Activ-
ity Index (Daghaghzadeh 2015), and theMayo Clinic Disease Ac-
tivity Index (Chojnacki 2011). The blood tests included C-reac-
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tive protein (CRP) (Chojnacki 2011), and cytokines/chemokines
(Mikocka-Walus 2016c).
One studymeasuredhospital admissions andneed for steroid treat-
ment (Goodhand 2012). None of the studies measured pain or
surgery.
For details of studies see Characteristics of included studies.
Excluded studies
Studies were excluded for not meeting the inclusion criteria
of study design (Drossmann 2014; Eirund 1998), presenting
data overlapping with another paper (Iskandar 2012; Iskandar
2011), lack of information regarding the efficacy of antidepres-
sants (Loftus 2011; Virta 2014), including combination ther-
apy without separate data on antidepressant efficacy (Xie 2014;
NCT02162862), no validated measure of outcomes (Mikocka-
Walus 2016b), no control group (Yanartas 2016), a control
group not comprised of IBD patients (Iskandar 2014), and a
trial registration without published results (NCT00126373). See
Characteristics of excluded studies.
Risk of bias in included studies
The results of the risk of bias analysis for the three controlled tri-
als are summarized in Figure 2 and Figure 3 (Chojnacki 2011;
Daghaghzadeh 2015; Mikocka-Walus 2016c). Table 1 reports
the Newcastle-Ottawa Scale results for the observational study
(Goodhand 2012). Mikocka-Walus 2016c was rated as low risk
of bias. Daghaghzadeh 2015 was rated as high risk of bias for
incomplete outcome data. The non-randomised controlled trial
was associated with low risk of bias on two items, unclear risk on
two items (blinding of outcome assessment and selective report-
ing) and high risk on three items (random sequence generation,
allocation concealment, blinding of participants and personnel)
(Chojnacki 2011).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
The observational study (Goodhand 2012), was considered to be
of reasonablemethodological quality andwas given a score of seven
stars. However, there were concerns with two items: representa-
tiveness of the cases and definition of controls. Cases were not
completely representative as some of them were excluded based
on the lack of data (e.g. when the date of commencement of the
antidepressant was missing). The definition of controls was con-
sidered incomplete as it did not mention the history of outcome
in this group. Importantly, this study was non-randomised and as
such is likely to be associated with a higher risk of bias than RCTs.
Allocation
Random sequence generation was rated as low risk of bias in two
studies (Daghaghzadeh 2015;Mikocka-Walus 2016c), and as high
risk in the non-randomised controlled trial (Chojnacki 2011).
Allocation concealment was rated as high risk of bias in one study
(Chojnacki 2011), as low risk in two studies (Daghaghzadeh 2015;
Mikocka-Walus 2016c).
Blinding
Blinding of participants and personnel was judged to be adequate
in two studies (Daghaghzadeh 2015;Mikocka-Walus 2016c), and
high risk of bias in one study (Chojnacki 2011). Blinding of
outcome assessment was judged to be adequate in two studies
(Daghaghzadeh 2015; Mikocka-Walus 2016c), and unclear risk
of bias in one study (Chojnacki 2011).
Incomplete outcome data
One study was judged to be at high risk of bias for Incom-
plete outcome data (Daghaghzadeh 2015), while two studies were
judged to be at low risk of bias for this item (Chojnacki 2011;
Mikocka-Walus 2016c).
Selective reporting
Selective reporting was considered at low risk of bias in two studies
(Daghaghzadeh 2015; Mikocka-Walus 2016c), and unclear risk
of bias in one study (Chojnacki 2011).
Other potential sources of bias
The three trials were considered at low risk of bias for other types
of bias (Chojnacki 2011; Daghaghzadeh 2015; Mikocka-Walus
2016c) .
Effects of interventions
See: Summary of findings for the main comparison
Antidepressants compared to placebo for inflammatory bowel
disease
18Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 1: Antidepressants versus placebo
Overall, four studies have contributed to this comparison
(Chojnacki 2011; Daghaghzadeh 2015; Goodhand 2012;
Mikocka-Walus 2016c).
Primary outcome measures
Anxiety
Three studies examined the effect of antidepressants on symp-
toms of anxiety (Chojnacki 2011; Daghaghzadeh 2015;Mikocka-
Walus 2016c).
At 12 weeks, using the HADS, Daghaghzadeh 2015 reported a
mean score of 6.11 + 3 in the antidepressant group (n = 22) com-
pared to 8.5 + 3.45 in the placebo group (n = 22) (MD -2.39,
95% -4.30 to -0.48; low certainty evidence, see Analysis 1.1 and
Summary of findings for the main comparison).
At 12 months, two trials reported that symptoms of anxiety were
improved in participants receiving antidepressants compared to
placebo (Chojnacki 2011; Mikocka-Walus 2016c). We initially
attempted to pool these studies using the SMD but a very high
degree of heterogeneity was detected (I2= 87%). Thus we report
the results for each trial separately. Using the HARS, Chojnacki
2011 reported a mean score of 12.65 + 3.76 in the antidepressant
group (n = 30) compared to 17.85 + 3.33 in the placebo group (n =
30) (MD -5.20, 95% CI -7 to -3.40; very low certainty evidence).
Using the HADS, Mikocka-Walus 2016c reported a mean score
of 3.8 + 2.5 in the antidepressant group (n = 14) compared to
4.2 + 4.9 in the placebo group (n = 12) (MD -0.40, 95% -3.47
to 2.67, low certainty evidence; See Analysis 1.2 and Summary of
findings for the main comparison).
Depression
Three studies examined the effect of antidepressants on symptoms
of depression (Chojnacki 2011; Daghaghzadeh 2015; Mikocka-
Walus 2016c).
At 12 weeks, using the HADS, Daghaghzadeh 2015 reported a
mean score of 7.47 + 2.42 in the antidepressant group (n = 22)
compared to 10.5 + 3.57 in the placebo group (n = 22) (MD -
3.03, 95% CI -4.83 to -1.23, low certainty evidence; see Analysis
1.3 and Summary of findings for the main comparison).
At 12 months, two trials reported that symptoms of depression
were improved in participants receiving antidepressants compared
to placebo (Chojnacki 2011; Mikocka-Walus 2016c). We initially
attempted to pool these studies using the SMD but a very high
degree of heterogeneity was detected (I2= 89%). Thus we report
the results for each trial separately. Using the BDI, Chojnacki 2011
reported a mean score of 9.6 + 2.76 in the antidepressant group
(n = 30) compared to 16.35 + 5.41 in the placebo group (n = 30)
(MD -6.75, 95% CI -8.92 to -4.58; very low certainty evidence).
Using the HADS, Mikocka-Walus 2016c reported a mean score
of 2.9 + 2.8 in the antidepressant group (n = 14) compared to
3.1 + 3.4 in the placebo group (n = 12) (MD -0.20, 95% -2.62
to 2.22, low certainty evidence; See Analysis 1.4 and Summary of
findings for the main comparison).
Secondary outcome measures
Adverse events
Adverse events were reported in three studies, with nausea being
an adverse event common to all three studies (Chojnacki 2011;
Daghaghzadeh 2015; Mikocka-Walus 2016c).
At 12weeks, higher rates of nauseawere reported in the antidepres-
sant group compared to placebo (Daghaghzadeh 2015). Thirty-
two per cent (7/22) of participants in the antidepressant group
reported nausea compared to nine per cent (2/22) of placebo par-
ticipants (RR 3.50, 95% CI 0.82 to 15.01; very low certainty ev-
idence). The very low GRADE rating was due to a small sample
size and incomplete outcome data.
At 12 months, two trials showed no group difference in nausea
between those taking antidepressants and placebo (Chojnacki
2011; Mikocka-Walus 2016c). Thirteen per cent (6/44) of those
taking antidepressants reported nausea compared to two per cent
(1/42) of placebo participants (RR 4.02, 95% CI 0.74 to 22.03).
Adverse events in the group who received antidepressants included
nausea, headache, dizziness, drowsiness, sexual problems, insom-
nia, fatigue, low mood/anxiety, dry mouth, poor sleep, restless
legs and hot flushes. Adverse events in the control group in-
cluded dizziness, insomnia and muscle spasms (Daghaghzadeh
2015; Mikocka-Walus 2016c).
Mikocka-Walus 2016c reported on the number of participants
who had an adverse event. Fifty-seven per cent (8/14) of those
in the antidepressant group reported adverse events compared to
25% (3/12) of the placebo group (RR 2.29, 95% CI 0.78 to 6.73,
low certainty evidence; See Analysis 1.5 and Summary of findings
for the main comparison).
Serious adverse events
Serious adverse events were not reported by the included studies.
Study withdrawal due to adverse events
One RCT examined the effect of antidepressants on study with-
drawal due to adverse events at 12 weeks (Daghaghzadeh 2015),
and one RCT examined the effect of antidepressants on study
withdrawal due to adverse events at 12 months (Mikocka-Walus
2016c).
At 12 weeks, no group difference in study withdrawal due to ad-
verse events was observed, with 4% (1/22) of participants tak-
ing antidepressants withdrawing from the study due to adverse
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events (adverse event type not reported) compared to 0% (0/22)
of placebo group participants (RR 3, 95% CI 0.13 to 69.9; see
Analysis 1.8).
At 12 months, no group difference in study withdrawal due to
adverse events was observed, with 7% (1/14) of participant taking
antidepressants withdrawing from the study due to adverse events
(including poor sleep, anxiety, restless legs) compared to 0% (0/
12) of placebo group participants (RR 2.6, 95% CI 0.12 to 58.5;
see Analysis 1.9).
Quality of life
One RCT examined the effect of antidepressants on QoL at 12
weeks (Daghaghzadeh 2015) and one RCT examined the effect of
antidepressants on QoL at 12 months (Mikocka-Walus 2016c).
Both studies used the WHOQOL-BREF questionnaire.
Physical QoL
At 12 weeks, Daghaghzadeh 2015 reported a mean score of 60.24
+ 12.94 in the antidepressant group (n = 22) compared to 49.52
+ 10.12 in the placebo group (n = 22) (MD 10.72, 95% CI 3.86
to 17.58, low certainty evidence; See Analysis 1.10 and Summary
of findings for the main comparison).
At 12 months, Mikocka-Walus 2016c reported a mean score of
68.83 + 13.34 in the antidepressant group (n = 14) compared to
66.66 + 21.72 in the placebo group (n = 12) (MD 2.17, 95%
CI -11.97 to 16.31, low certainty evidence; See Analysis 1.11 and
Summary of findings for the main comparison).
Psychological QoL
At 12 weeks, Daghaghzadeh 2015 reported a mean score of 51.81
+ 13.6 in the antidepressant group (n = 22) compared to 43.5 +
11.94 in the placebo group (n = 22) (MD 8.31, 95% CI 0.75 to
15.87, low certainty evidence; See Analysis 1.12 and Summary of
findings for the main comparison).
At 12 months, Mikocka-Walus 2016c reported a mean score of
75.37 + 14.84 in the antidepressant group (n = 14) compared to
72.22 + 16.79 in the placebo group (n = 12) (MD 3.15, 95%
CI -9.12 to 15.42, low certainty evidence; See Analysis 1.13 and
Summary of findings for the main comparison).
Social QoL
At 12 weeks, Daghaghzadeh 2015 reported a mean score of 51.2
+ 15.1 in the antidepressant group (n = 22) compared to 38.88 +
12.12 in the placebo group (n = 22) (MD 12.32, 95% CI 4.23 to
20.41, low certainty evidence; See Analysis 1.14 and Summary of
findings for the main comparison).
At 12 months, Mikocka-Walus 2016c reported a mean score of
73.48 + 18.56 in the antidepressant group (n = 14) compared to
75 + 23.19 in the placebo group (n = 12) (MD -1.52, 95% CI
-17.85 to 14.81, low certainty evidence; See Analysis 1.15 and
Summary of findings for the main comparison).
Environmental QoL
At 12 weeks, Daghaghzadeh 2015 reported a mean score of 51.79
+ 10.24 in the antidepressant group (n = 22) compared to 44.13
+ 12.27 in the placebo group (n = 22) (MD 7.66, 95% CI 0.98
to 14.34, low certainty evidence; See Analysis 1.16 and Summary
of findings for the main comparison).
At 12 months, Mikocka-Walus 2016c reported a mean score of
73.86 + 14.41 in the antidepressant group (n = 14) compared to
75.69 + 9.85 in the placebo group (n = 12) (MD -1.83, 95%
CI -11.21 to 7.55; low certainty evidence; See Analysis 1.17 and
Summary of findings for the main comparison).
The low GRADE rating at both 12 weeks and 12 months was
due to very serious imprecision (26 participants) in one study
(Mikocka-Walus 2016c), and incomplete outcome data and im-
precision (44 participants) in the other study (Daghaghzadeh
2015).
Clinical remission
One trial reported on remission rates at 12 months post treatment
(Mikocka-Walus 2016c). In the group receiving an antidepressant,
64% (9/14) of participants remained in remission (based onCDAI
and faecal calprotectin) compared to 66% (8/12) in the placebo
group (RR 0.96, 95% CI 0.55 to 1.69, low certainty evidence; see
Analysis 1.18 and Summary of findings for themain comparison).
Three studies used a disease activity index to measure disease
activity (Chojnacki 2011; Daghaghzadeh 2015; Mikocka-Walus
2016c). This post hoc outcome was not pre-specified in our pro-
tocol.
At 12 weeks, using the Lichtiger Colitis Activity Index,
Daghaghzadeh 2015 reported a mean score of 4.52 + 11.63 in
the antidepressant group (n = 22) compared to 6.83 + 2.09 in the
placebo group (n = 22) (MD -2.31, 95% CI -3.42 to -1.20; See
Analysis 1.19).
At 12 months, two trials reported that disease activity was im-
proved in the group taking antidepressants as compared to placebo
(Chojnacki 2011;Mikocka-Walus 2016c). We initially attempted
to pool these studies using the SMD but a very high degree of
heterogeneity was detected (I2= 87%). Thus we report the results
for each trial separately. Using the Mayo Clinic Disease Activity
Index, Chojnacki 2011 reported a mean score of 3.05 + 1.36 in
the antidepressant group (n = 30) compared to 4.65 + 1.69 in the
placebo group (n = 30) (MD -1.60, 95% CI -2.38 to -0.82; See
Analysis 1.20). Using the CDAI, Mikocka-Walus 2016c reported
a mean score of 84.4 + 82.5 in the antidepressant group compared
(n = 14) to 60.63 + 46.5 in the placebo group (n = 12) (MD23.77,
95% CI -26.82 to 74.36; See Analysis 1.20).
No study collected data on clinical remission at longitudinal fol-
low-up beyond trial completion.
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Relapse
One non-randomised trial reported on endoscopic relapse up to
12 months post treatment (Chojnacki 2011). At 12 months, 0%
(0/30) of participants in the antidepressant group had endoscopic
relapse compared to 10% (3/30) of placebo group participants
(RR 0.14, 95% CI 0.01 to 2.65, very low certainty evidence; see
Analysis 1.21 and Summary of findings for themain comparison).
The following relevant post hoc outcomes were not pre-specified
in our review protocol: relapse using clinician’s assessment, faecal
calprotectin and blood tests (CRP, cytokines/chemokines).
Goodhand 2012 reported on the number of relapses (clinician
assessed based on symptoms/blood tests) in the year preceding
treatment with antidepressants and in the year after the treatment
commenced. In the year after starting an antidepressant, patients
treated with an antidepressant had fewer relapses than controls
(median[range] = 0 [0-4) versus 1 [0-3]).
In one trial (Mikocka-Walus 2016c) there was no group differ-
ence in the relapse rate as measured using faecal calprotectin at
12 months (post treatment), with 7% (1/14) of the participants
in the antidepressant group relapsing (faecal calprotectin > 200)
compared to 0% (0/12) of the placebo group (MD 2.60, 85% CI
0.12 to 58.48; See Analysis 1.22).
Regarding blood tests, one trial reported data on CRP (Chojnacki
2011), while another trial reported data for cytokines and
chemokines (Mikocka-Walus 2016c). Chojnacki 2011 reported a
mean CRP of 6.99 + 5.65 in the antidepressant group (n = 30)
compared to 9.40 + 6.78 in the placebo group (n = 30) (MD -
2.41, 95% CI -5.57 to 0.75; See Analysis 1.23).
Mikocka-Walus 2016c reported ameanproportionofTHEffector
Memory RA cells of 45.8 + 4.5 in the antidepressant group (n =
14) compared to 39.7 + 3.1 in the placebo group (n = 12) (MD
6.10, 95% CI 3.16 to 9.04; See Analysis 1.24).
Mikocka-Walus 2016c reported amean proportion of TCEffector
Memory RA cells of 3.5 + 0.48 in the antidepressant group (n =
14) compared to 4.75 + 0.9 in the placebo group (n = 12) (MD -
1.25, 95% CI -1.82 to -0.68; See Analysis 1.25).
Regarding interleukin-10 (IL-10) secretion, Mikocka-Walus
2016c reported a mean of CD3/CD28 stimulated cytokine con-
centrations in peripheral blood mononuclear cells supernatants of
525.3 + 93.2 in the antidepressant group (n = 14) compared to
222.9 + 63.2 in the placebo group (n = 12) (MD 302.4, 95% CI
241.89 to 362.91; See Analysis 1.26).
No study collected data on relapse at longitudinal follow-up be-
yond trial completion.
Pain severity
None of the included studies examined the impact of antidepres-
sants on pain.
Hospital admissions
Hospital admissions were included as an outcome in only one
study (Goodhand 2012), and thus a meta-analysis was not con-
ducted. At 12-month follow-up, no participants in either group
had hospital admissions due to IBD.
Surgery
The included studies did not examine the impact of antidepres-
sants on the need for surgery.
Need for steroid treatment
The need for steroid treatment was included as an outcome in only
one study (Goodhand 2012). At 1-year follow-up, no participants
in the antidepressant group (0/29) required steroids compared to
3% (1/29) of those in the control group (MD 0.33, 95% CI 0.01
to 7.86; See Analysis 1.27).
D I S C U S S I O N
Up to 30% of people with IBD take antidepressants (Fuller-
Thomson 2006; Haapamaki 2013; Mikocka-Walus 2012). De-
spite the clinical relevance of the present topic, there were only
four studies (examining 188 people in total) of sufficient quality
to include in this systematic review.
The review cautiously suggests that antidepressants improved the
symptoms of anxiety and depression. There was no group differ-
ence in nausea or study withdrawal due to adverse events. Antide-
pressants were associated with some benefits for QoL and disease
activity. However, the GRADE analysis indicated that the overall
certainty of the evidence was very low, due to a small sample size,
incomplete outcome data, and heterogeneity in population and
antidepressant treatment type, thusmore well-designed studies are
needed. Future trials examining the role of antidepressants in IBD
are therefore needed to clarify whether the present findings are
consistent.
Summary of main results
Up to 30% of people with IBD take antidepressants (Fuller-
Thomson 2006; Haapamaki 2013; Mikocka-Walus 2012). De-
spite the clinical relevance of the present topic, there were only
four studies (including 188 participants) meeting the inclusion
criteria (Chojnacki 2011; Daghaghzadeh 2015; Goodhand 2012;
Mikocka-Walus 2016c). Two studies were double-blind RCTs
(Daghaghzadeh 2015; Mikocka-Walus 2016c). One study was
non-randomised controlled trial (Chojnacki 2011), and the fi-
nal study was an observational retrospective case-matched study
(Goodhand 2012).
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Symptoms of anxiety and depression were improved at 12
weeks and 12 months in antidepressant participants compared to
placebo. There were no group differences in adverse events at 12
months or study withdrawal due to adverse events at 12 weeks
or 12 months. Physical, Psychological, Social and Environmen-
tal QoL were improved at 12 weeks with no group differences
at 12 months. Disease activity as measured by disease activity in-
dices was also improved in the group receiving antidepressants.
However, there was no group difference in clinical remission at 12
months (based on the CDAI and faecal calprotectin), or relapse
rate at 12 months (based on endoscopy or faecal calprotectin).
There were no group differences in hospital admissions or need
for steroid treatment. Pain severity or surgery were not reported
in the included studies.
Overall completeness and applicability of
evidence
The results of this review are applicable to adults with Crohn’s
disease and ulcerative colitis, though at this point it is unclear
if patients with either IBD subtype may benefit more from an-
tidepressant treatment. The studies included in this review as-
sessed different IBD populations. For example, one study limited
the intervention to the participants reporting symptoms of anxi-
ety and depression (Chojnacki 2011), while the other studies did
not. One study included participants with mixed disease activ-
ity (Goodhand 2012), while the other studies included partici-
pants who were in remission. Two studies included participants
with Crohn’s disease and ulcerative colitis (Daghaghzadeh 2015;
Goodhand 2012), while the other studies examined just one IBD
subtype. The overall evidence base is not complete. All of the in-
cluded studies had small sample sizes and we were unable to collect
data for some of our pre-specified outcomes (e.g. pain severity and
surgery). Several outcomes were only reported by one study (e.g.
CRP, cytokines, faecal calprotectin, endoscopic relapse, hospital
admissions, need for steroids). The four studies assessed different
classes of antidepressants, thus the evidence supporting the use of
any particular type of antidepressant is sparse. The certainty of
this evidence was very low and further studies are needed before
firm conclusions can be drawn.
Quality of the evidence
One RCT was rated as low risk of bias (Mikocka-Walus 2016c).
The other RCT was rated as high risk of bias for incomplete out-
come data. The non-randomised controlled trial was rated as high
risk of bias for random sequence generation, allocation conceal-
ment, and blinding of participants and personnel. Although the
observational study scored well on the Newcastle-Ottawa scale, it
is still considered to be at high risk of bias in comparison to RCTs
given its observational design (Goodhand 2012).
The GRADE analysis indicated that the overall certainty of the
evidence supporting the outcomes of anxiety, depression, QoL,
adverse events, and disease activity was low or very low due to very
serious imprecision and high risk of bias (incomplete outcome
data) in one study.
Potential biases in the review process
Measures were taken to ensure the reviewers who co-authored one
of the included trials would not extract data or assess study qual-
ity (Mikocka-Walus 2016c). Authors not involved in the previous
trial (SLP, SK, JP) undertook this task. All studies were assessed
for inclusion by two independent authors and any disagreements
were resolved by a third author. All data were extracted indepen-
dently by two authors. Further, to reduce any language bias, lan-
guage restrictions were not imposed on the current review and the
included Polish study was translated (Chojnacki 2011), as well as
the two non-English excluded studies (Eirund 1998; Xie 2014).
The limitations of the present review include the deviation from
anRCTdesign usually used in effectiveness reviews.We decided to
broaden our inclusion criteria to include non-randomised studies
in order to increase the number of included studies in the review.
We decided against conducting a subgroup analysis based on type
of IBD (i.e. Crohn’s disease or ulcerative colitis) due to the very
small sample size per comparison group. We also decided to use
a fixed-effect model for our analysis even when heterogeneity was
considerable. We realise this decision may be controversial, but
it was dictated by the desire to reduce bias inherent in reviews
including studies with small sample sizes. While we attempted a
meta-analysis, only the data for nausea at 12 months could be
combined as the heterogeneity was low. All other data where two
studies are presented on the forest plot could not be combined
due to high levels of heterogeneity.
Agreements and disagreements with other
studies or reviews
The results of this review agree with the two previous reviews
which relied on data synthesis only (Macer 2017; Mikocka-Walus
2006). The present review is the first attempt at a meta-analysis
in the area.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results for the outcomes assessed in this review are uncertain
and no firm conclusions regarding the efficacy and safety of an-
tidepressants in IBD can be drawn.
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Implications for research
Adequately-powered high quality trials examining the role of an-
tidepressants as an adjuvant therapy to manage psychological and
physical symptoms of IBD are warranted. Future studies should
employ blinded RCT designs which are the gold standard for drug
trials. These studies should include follow-up beyond post-treat-
ment, while at the same time developing solutions to address at-
trition, which was a concern in one study included in this review
(Daghaghzadeh 2015). Attrition could result from adverse events,
however, this was not confirmed by the present review, with no
group differences in study drop out due to adverse events. The
inclusion of objective markers of disease activity is strongly rec-
ommended. Testing antidepressants from different groups is also
warranted, as at present it is unclear if one group of antidepressants
is superior to the other groups. The present review shows that the
positive results occur across different classes of antidepressant and
thus there is the potential for flexibility and tailoring of treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chojnacki 2011
Methods Country: Poland
Design: Single-blinded, non-randomised controlled trial
Not multicentre
Duration of trial: 12 months
Study aim: To evaluate the influence of tianeptine (an atypical antidepressant) on the
mental and somatic status of study participants
Participants Population description: Ulcerative colitis patients in remission with symptoms of anx-
iety or depression
Setting: No information provided
Inclusion criteria: Ulcerative colitis in remission for six months (no inflammation as
evidenced endoscopically and using Mayo Index)
Exclusion criteria: No information provided
Method of participant recruitment: No information provided
Total number of participants eligible for the study: n = 60
Participants allocated for each arm of the study (no randomisation): Intervention
group n = 30, Comparison group n = 30
Participant completion of follow up: n = 30 (Intervention) n = 30 (Comparison)
Age: Mean age for the study population in both groups of n = 60: 30.6 years + 8.8
Gender: n = 39 women and n = 21 men in both groups in total
Race/ethnicity: Not reported
Interventions Intervention group
A dose of 12.5 mg of an antidepressant tianeptine was administered for 12 months, three
times daily
Co-intervention: 1 g of aminosalicylates (mesalazine) twice daily as usual treatment
Comparison group
The comparison group received a placebo for 12 months. Dose and frequency not
reported
Co-intervention: 2 g of aminosalicylates (mesalazine) daily as usual treatment
Mode of delivery: Oral tablet
Outcomes Outcomes collected: Disease activity, CRP, anxiety, depression
Time points measured and reported:Baseline, threemonths, six months, nine months,
12 months
How were outcomes assessed?
Disease activity: baseline and 12 months - colonoscopy, three, six, nine months - sig-
moidoscopy; Mayo Clinic Disease Activity Index
CRP: blood test
Anxiety: Hamilton Anxiety Rating Scale
Depression: Beck Depression Inventory
Outcome measures well-established: Yes
Missing data: None reported
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Chojnacki 2011 (Continued)
Notes Sample size calculation not reported
Safety was monitored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non randomised trial
Allocation concealment (selection bias) High risk No randomisation conducted
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Only participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) Unclear risk The trial was not registered on any registry
Other bias Low risk No other bias identified
Daghaghzadeh 2015
Methods Country: Iran
Design: Randomised, double-blind, controlled study
Not multicentre
Duration of trial: 12 weeks
Study aim: To assess efficacy of duloxetine (SNRI) on anxiety, depression, severity of
symptoms and QoL in patients with IBD
Participants Population description: IBD patients in remission with no anxiety or depression
Setting: Outpatient gastro clinic at Alzahra hospital in Iran
Inclusion criteria: 18 to 65 years of age, current diagnosis of IBD, no flare-up of disease
in last six months
Exclusion criteria:
Serious medical condition that may interfere with safe study participation
Lactation, pregnancy, inadequate contraception
Suicidal intention or plan
Lifetime bipolar, psychotic or obsessive-compulsive disorder
Substance use disorders
Major depressive disorder or anxiety disorders in the past six months
Treatment with any psychotropic medication within seven days before study
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Daghaghzadeh 2015 (Continued)
Participants who were unable to tolerate a dose of 60 mg daily were excluded from the
study
Method of participant recruitment: IBD patients referred to the outpatient gastroen-
terology clinic at Alzahra hospital; participants were recruited by physicians and specialty
IBD services
Total number of participants eligible for the study: n = 62
Participants randomised for each arm of the study: Intervention group n = 22, Com-
parison group n = 22
Participant completion for each arm of the study: Intervention group n = 17 (UC n
= 10, CD n = 7), Comparison group n = 18 (UC n = 12, CD n = 6)
Age: Intervention: 37.8 + 7.8, Comparison: 38.11 + 8.5
Gender: Intervention: n = 8 women (47.1%) and n = 9 men (52.9%)
Comparison: n = 8 women (44.4%) and n = 10 men (56.6%)
Interventions Intervention group
Participants started with 30 mg of an antidepressant duloxetine once a day for one week;
and then 60 mg daily for 11 weeks. Self-use at home
Co-intervention: 2 to 4 g of mesalazine daily
Comparison group
The comparison group received a placebo for 12 weeks in the same form and packages
as duloxetine. Participants started with 30 mg of placebo once a day for one week; and
then 60 mg daily for 11 weeks. Self-use at home
Co-intervention: 2-4g of mesalazine daily
Mode of delivery: Oral tablet (blister packages)
Outcomes Outcomes collected: Anxiety, depression, severity of symptoms, QoL in IBD
Time points measured and reported: Baseline and at 12 weeks (end of study)
How were outcomes assessed?
Anxiety - HADS
Depression - HADS
Severity of IBD - LCAI
QoL - WHOQOL -BREF
Outcome measures well-established: Yes
Missing data: Five missing in the experimental and four in the control group
Notes Sample size calculation not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation performed by third party
physician using tables of random numbers
Allocation concealment (selection bias) Low risk Allocation was performed centrally by a
pharmacy
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Daghaghzadeh 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Questionnaire scores were assessed by a
psychologist who was not informed about
grouping of the subjects
Incomplete outcome data (attrition bias)
All outcomes
High risk Only completers’ data have been analysed
No intention to treat, data in tables do not
report on all participants allocated to inter-
vention/controls
Selective reporting (reporting bias) Low risk Study registered on Iranian Registry of
Clinical Trials, reported on all pre-specified
primary outcomes and 2 out of 4 secondary
adverse events outcomes (did not specifi-
cally report on rates of vomiting and dys-
pepsia however listed all adverse events and
these two were not reported by the partici-
pants)
Other bias Low risk No other bias identified
Goodhand 2012
Methods Country: UK
Design: A retrospective, case-matched observational study with a comparison group
Not multicentre
Duration of study: Two years
Study aim: To explore whether antidepressants used to treat concurrent mood disorders in IBD would improve
disease course int he study population
Participants Population description: Index patients diagnosed with IBD and treated with antidepressants for mood disorders,
attending the specialist IBD outpatient clinics
Setting: Barts and the London NHS Trust - tertiary adult and paediatric IBD centre in London, UK
Inclusion criteria:
Intervention group: Index patients with IBD diagnosed by conventional endoscopic, radiological, and histological
criteria attending transition and adult outpatient clinics and treated with antidepressant for mood disorders
Comparison group: Consecutive attendees to specialist IBD outpatient clinics betweenMarch and August 2010, who
would potentially match each index patient on the grounds of gender, age, disease duration, baseline medications,
surgeries, relapse rate in year one. Wherever possible data were sampled on disease course in the years one and two
matched to the equivalent time frames for duration of antidepressant therapy in the index case
Exclusion criteria:
Intervention group: Patients in whom a date of commencement of the antidepressant was unknown, or where the
use of the antidepressant predated the diagnosis of IBD, or where subsequent follow-up was for less than a year, were
excluded
Method of participant recruitment: Intervention group: electronic patient records. Comparison group: consecutive
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Goodhand 2012 (Continued)
attendees to specialist IBD outpatient clinics
Number of participants eligible for the study: Intervention: n = 45, Comparison: n = 2449
Total number of participants in each arm of the study: Intervention group n = 29 (UC n = 14, CD n = 15, active
disease n =12), Comparison group n = 29 (UC n = 14, CD n = 15, active disease n = 12)
Participant completion for each arm of the study: Intervention group n = 29, Comparison group n = 29
Age: Median range for each arm: Intervention: 26 years [13 to 72], Comparison: 29 years [12 to 62]
Gender - male (n = value): Intervention: n = 12 (41%) and Comaprison: n = 12 (41%)
Interventions Intervention group
Antidepressant used to treat a concomitant mood disorder:
SSRI (Selective Serotonin Reuptake Inhibitors): citalopram, fluoxetine, sertraline, paroxetine; TCA (Tricyclic antide-
pressants): amitriptyline, lofepramine; NaSSa: mirtazapine; SNRI: venlafaxine)
Dose: clinical ranges
Co-intervention: treatment as usual - IBD medication
Comparison group
Matched control group without placebo, only treatment as usual
Co-intervention: treatment as usual - IBD medication
Mode of delivery: Not reported
Outcomes Outcomes collected: Number of relapses, number of endoscopic procedures, number of hospital admissions and
outpatient visits, number of courses of steroids, relapse related use of IBDmedication: e.g. increase in 5-aminosalicylate
dosage or introduction of antibiotics, immunosuppressants or anti-tumour necrosis factor therapy
Time points measured and reported: End of year 1 and end of year 2
How were outcomes assessed? Retrospectively, from the electronic patients records
Outcome measures well-established: Not reported
Missing data: None missing
Notes
Mikocka-Walus 2016c
Methods Country: Australia
Design: Parallel randomised, double-blind, placebo controlled study
Is it a multicentre study? Yes, two hospitals in South Australia participated
Duration of trial: 12 months
Study aim: To examine the impact of low-dose antidepressant, fluoxetine (SSRI), in
addition to standard therapy, on disease activity, disease remission rate, QoL and/or
mental health in people with CD, as compared to placebo
Participants Population description: Adult patients with clinically established diagnosis of CD in
clinical remission, but who had flared CD in the last 12 months
Setting: Treatment was delivered via hospital pharmacies, no further details reported
Inclusion criteria: Adult patients with clinically established diagnosis of CD in clinical
remission, but who had flared CD in the last 12 months
Exclusion criteria:
Serious uncontrolled mental illness
Alcohol/substance dependent
Cognitive impairment, taking antidepressants, receiving psychotherapy
Taking steroids (prednisolone >15 mg/day or equivalent)
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Mikocka-Walus 2016c (Continued)
Pregnant/breastfeeding or planning to become pregnant
Taking any medications listed as contraindicated with fluoxetine
Method of participant recruitment: None reported
Total number of participants eligible for the study (n = value) : n = 556
Participants randomised for each arm of the study: Intervention group n = 14, Com-
parison group n = 12
Participant completion for each arm of the study:
Intervention group n = 10 (n = 1 did not receive intervention, n = 3 discontinued)
Comparison group n = 8 (n = 2 did not receive intervention, n = 2 discontinued)
Participant completion of follow-up (n=value): Intervention n = 10, Comparison n
= 7
Age: Intervention: 38.07 years [13.6], Comparison: 36.67 years [13.2]
Gender, male (n = value): Intervention: n = 8, Comparison n = 6
Interventions Intervention group
Participants with clinically established CD, with quiescent or only mild disease were
randomly assigned to receive 20 mg of fluoxetine daily for 12 months
Co-intervention: patients remained on their current IBD medication
Comparison group
Participants with clinically established CD, with quiescent or only mild disease were
randomly assigned to receive placebo daily for 12 months
Co-intervention: patients remained on their current IBD medication
Mode of delivery: Oral tablet
Outcomes Outcomes collected:
Primary outcomes:
1. Change in CD remission rate as measured by the CDAI (cut off < 150)
2. Difference in means for quality of life measured by WHOQOL-BREF
Secondary outcomes:
3. Remission rates as measured by faecal calprotectin
4. HADS
5. Cytokine and chemokine levels
Time points measured and reported: Baseline, three, six and 12 months. For Cytokine
and chemokine levels: at six months
How were outcomes assessed?
Self-reported questionnaire for primary outcomes
Stool sample analysis for disease activity and blood sample analysis for cytokine and
chemokine levels
Outcome measures well-established: Yes
Missing data: Four missing in the experimental and four in the control group
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated sequence was used
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Mikocka-Walus 2016c (Continued)
Allocation concealment (selection bias) Low risk The statistician without patient contact
carried out the sequence generation while
the participating pharmacies allocated the
participants to groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blinding - participants received ei-
ther fluoxetine 20 mg daily or identically
looking placebo [i.e. gelatin capsules filled
with microcrystalline cellulose]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants blinded. Lab analysts (stool
and blood) were blinded. Questionnaires
were scored by a Research Assistant blinded
to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 23% withdrew and 30.7% missing out-
comes at 12 months
Even number of drop-outs between the in-
tervention and control group. Reasons for
drop-outs were described in the paper
Selective reporting (reporting bias) Low risk All outcomes reported as per the protocol
registeredwith the AustralianNewZealand
Trial Registry
Other bias Low risk No other bias identified
CRP: C-reactive protein
HARS: Hamilton Anxiety Rating Scale (HARS).
BDI: Beck Depression Inventory
SNRI: serotonin-norepinephrine reuptake inhibitors
IBD: inflammatory bowel disease
UC: ulcerative colitis
CD: Crohn’s disease
HADS: Hospital Anxiety and Depression Scale
LCAI: Lichtiger Colitis Activity Index
WHOQOL-BREF: World Health Organization Quality of Life short version questionnaire
SSRI: selective serotonin reuptake inhibitors
TCA: tricyclic antidepressants
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Drossmann 2014 Wrong design: an editorial
Eirund 1998 Wrong design: a case-report
Iskandar 2011 Data overlapping with those presented in Iskandar 2014
Iskandar 2012 Data overlapping with those presented in Iskandar 2014
Iskandar 2014 The control group were not IBD patients
Loftus 2011 No data on efficacy of antidepressant medication, the study estimates the risk of developing depression
Mikocka-Walus 2016b No validated outcome measures, this study focuses on perceived efficacy of antidepressant medication
NCT00126373 A trial registration without published results
NCT02162862 Study included combination therapy without separate data on antidepressant efficacy
Virta 2014 The study aimed to assess the use of antidepressants among adolescents with recent-onset IBD
No data on the efficacy of antidepressant were reported, the study only reported data on the frequency of
antidepressant use
Xie 2014 Study included combination therapy without separate data on antidepressant efficacy
Yanartas 2016 There was no control group in the study
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D A T A A N D A N A L Y S E S
Comparison 1. Antidepressants versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Anxiety at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Anxiety at 12 months 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Depression at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Depression at 12 months 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Adverse events at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Adverse events: nausea at 12
weeks
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Adverse events: nausea at 12
months
2 86 Risk Ratio (M-H, Fixed, 95% CI) 4.02 [0.74, 22.03]
8 Study withdrawal due to adverse
events at 12 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Study withdrawal due to adverse
events at 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Physical QoL at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11 Physical QoL at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12 Psychological QoL at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 Psychological QoL at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14 Social QoL at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15 Social QoL at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16 Environmental QoL at 12
weeks
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17 Environmental QoL at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18 Clinical remission at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
19 Disease activity at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20 Disease activity at 12 months 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
21 Endoscopic relapse at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
22 Relapse using faecal calprotectin
at 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
23 CRP at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
24 Cytokines TH Effector
Memory RA at 6 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
25 Cytokines TC Effector
Memory RA at 6 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26 Interleukin-10 at 6 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
27 Need for steroids at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Antidepressants versus placebo, Outcome 1 Anxiety at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 1 Anxiety at 12 weeks
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Daghaghzadeh 2015 (1) 22 6.11 (3) 22 8.5 (3.45) -2.39 [ -4.30, -0.48 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
(1) Hospital Anxiety and Depression Scale
Analysis 1.2. Comparison 1 Antidepressants versus placebo, Outcome 2 Anxiety at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 2 Anxiety at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chojnacki 2011 (1) 30 12.65 (3.76) 30 17.85 (3.33) -5.20 [ -7.00, -3.40 ]
Mikocka-Walus 2016c (2) 14 3.8 (2.5) 12 4.2 (4.9) -0.40 [ -3.47, 2.67 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
(1) Hamilton Anxiety Rating Scale
(2) Hospital Anxiety and Depression Scale
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Analysis 1.3. Comparison 1 Antidepressants versus placebo, Outcome 3 Depression at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 3 Depression at 12 weeks
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Daghaghzadeh 2015 (1) 22 7.47 (2.42) 22 10.5 (3.57) -3.03 [ -4.83, -1.23 ]
-4 -2 0 2 4
Favours Antidepressants Favours Placebo
(1) Hospital Anxiety and Depression Scale
Analysis 1.4. Comparison 1 Antidepressants versus placebo, Outcome 4 Depression at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 4 Depression at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chojnacki 2011 (1) 30 9.6 (2.76) 30 16.35 (5.41) -6.75 [ -8.92, -4.58 ]
Mikocka-Walus 2016c (2) 14 2.9 (2.8) 12 3.1 (3.4) -0.20 [ -2.62, 2.22 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
(1) Beck Depression Inventory
(2) Hospital Anxiety and Depression Scale
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Analysis 1.5. Comparison 1 Antidepressants versus placebo, Outcome 5 Adverse events at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 5 Adverse events at 12 months
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mikocka-Walus 2016c 8/14 3/12 2.29 [ 0.78, 6.73 ]
0.2 0.5 1 2 5
Favours Antidepressants Favours Placebo
Analysis 1.6. Comparison 1 Antidepressants versus placebo, Outcome 6 Adverse events: nausea at 12
weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 6 Adverse events: nausea at 12 weeks
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Daghaghzadeh 2015 7/22 2/22 3.50 [ 0.82, 15.01 ]
0.05 0.2 1 5 20
Favours Antidepressants Favours Placebo
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Analysis 1.7. Comparison 1 Antidepressants versus placebo, Outcome 7 Adverse events: nausea at 12
months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 7 Adverse events: nausea at 12 months
Study or subgroup Antidepressants Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chojnacki 2011 4/30 0/30 31.7 % 9.00 [ 0.51, 160.17 ]
Mikocka-Walus 2016c 2/14 1/12 68.3 % 1.71 [ 0.18, 16.65 ]
Total (95% CI) 44 42 100.0 % 4.02 [ 0.74, 22.03 ]
Total events: 6 (Antidepressants), 1 (Placebo)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Antidepressants Favours Placebo
Analysis 1.8. Comparison 1 Antidepressants versus placebo, Outcome 8 Study withdrawal due to adverse
events at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 8 Study withdrawal due to adverse events at 12 weeks
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Daghaghzadeh 2015 1/22 0/22 3.00 [ 0.13, 69.87 ]
0.01 0.1 1 10 100
Favours Antidepressants Favours Placebo
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Analysis 1.9. Comparison 1 Antidepressants versus placebo, Outcome 9 Study withdrawal due to adverse
events at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 9 Study withdrawal due to adverse events at 12 months
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mikocka-Walus 2016c 1/14 0/12 2.60 [ 0.12, 58.48 ]
0.01 0.1 1 10 100
Favours Antidepressants Favours Placebo
Analysis 1.10. Comparison 1 Antidepressants versus placebo, Outcome 10 Physical QoL at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 10 Physical QoL at 12 weeks
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Daghaghzadeh 2015 (1) 22 60.24 (12.94) 22 49.52 (10.12) 10.72 [ 3.86, 17.58 ]
-20 -10 0 10 20
Favours Placebo Favours Antidepressants
(1) WHOQOL - BREF
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Analysis 1.11. Comparison 1 Antidepressants versus placebo, Outcome 11 Physical QoL at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 11 Physical QoL at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mikocka-Walus 2016c (1) 14 68.83 (13.34) 12 66.66 (21.72) 2.17 [ -11.97, 16.31 ]
-20 -10 0 10 20
Favours Placebo Favours Antidepressants
(1) WHOQOL
Analysis 1.12. Comparison 1 Antidepressants versus placebo, Outcome 12 Psychological QoL at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 12 Psychological QoL at 12 weeks
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Daghaghzadeh 2015 (1) 22 51.81 (13.6) 22 43.5 (11.94) 8.31 [ 0.75, 15.87 ]
-10 -5 0 5 10
Favours Placebo Favours Antidepressants
(1) WHOQOL - BREF
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Analysis 1.13. Comparison 1 Antidepressants versus placebo, Outcome 13 Psychological QoL at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 13 Psychological QoL at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mikocka-Walus 2016c (1) 14 75.37 (14.84) 12 72.22 (16.79) 3.15 [ -9.12, 15.42 ]
-10 -5 0 5 10
Favours Placebo Favours Antidepressants
(1) WHOQOL
Analysis 1.14. Comparison 1 Antidepressants versus placebo, Outcome 14 Social QoL at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 14 Social QoL at 12 weeks
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Daghaghzadeh 2015 (1) 22 51.2 (15.1) 22 38.88 (12.12) 12.32 [ 4.23, 20.41 ]
-20 -10 0 10 20
Favours Placebo Favours Antidepresssants
(1) WHOQOL - BREF
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Analysis 1.15. Comparison 1 Antidepressants versus placebo, Outcome 15 Social QoL at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 15 Social QoL at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mikocka-Walus 2016c (1) 14 73.48 (18.56) 12 75 (23.19) -1.52 [ -17.85, 14.81 ]
-20 -10 0 10 20
Favours Placebo Favours Antidepresssants
(1) WHOQOL
Analysis 1.16. Comparison 1 Antidepressants versus placebo, Outcome 16 Environmental QoL at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 16 Environmental QoL at 12 weeks
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Daghaghzadeh 2015 (1) 22 51.79 (10.24) 22 44.13 (12.27) 7.66 [ 0.98, 14.34 ]
-10 -5 0 5 10
Favours Placebo Favours Antidepressants
(1) WHOQOL - BREF
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Analysis 1.17. Comparison 1 Antidepressants versus placebo, Outcome 17 Environmental QoL at 12
months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 17 Environmental QoL at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mikocka-Walus 2016c (1) 14 73.86 (14.41) 12 75.69 (9.85) -1.83 [ -11.21, 7.55 ]
-10 -5 0 5 10
Favours Placebo Favours Antidepressants
(1) WHOQOL
Analysis 1.18. Comparison 1 Antidepressants versus placebo, Outcome 18 Clinical remission at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 18 Clinical remission at 12 months
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mikocka-Walus 2016c 9/14 8/12 0.96 [ 0.55, 1.69 ]
0.1 0.2 0.5 1 2 5 10
Favours Antidepressants Favours Placebo
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Analysis 1.19. Comparison 1 Antidepressants versus placebo, Outcome 19 Disease activity at 12 weeks.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 19 Disease activity at 12 weeks
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Daghaghzadeh 2015 (1) 22 4.52 (1.63) 22 6.83 (2.09) -2.31 [ -3.42, -1.20 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
(1) Lichtiger Colitis Activity Index
Analysis 1.20. Comparison 1 Antidepressants versus placebo, Outcome 20 Disease activity at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 20 Disease activity at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chojnacki 2011 (1) 30 3.05 (1.36) 30 4.65 (1.69) -1.60 [ -2.38, -0.82 ]
Mikocka-Walus 2016c (2) 14 84.4 (82.5) 12 60.63 (46.5) 23.77 [ -26.82, 74.36 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
(1) Mayo Clinic Disease Activity Index
(2) Crohn’s Disease Activity Index
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Analysis 1.21. Comparison 1 Antidepressants versus placebo, Outcome 21 Endoscopic relapse at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 21 Endoscopic relapse at 12 months
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chojnacki 2011 0/30 3/30 0.14 [ 0.01, 2.65 ]
0.01 0.1 1 10 100
Favours Antidepressants Favours Placebo
Analysis 1.22. Comparison 1 Antidepressants versus placebo, Outcome 22 Relapse using faecal calprotectin
at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 22 Relapse using faecal calprotectin at 12 months
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mikocka-Walus 2016c 1/14 0/12 2.60 [ 0.12, 58.48 ]
0.01 0.1 1 10 100
Favours Antidepressants Favours Placebo
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Analysis 1.23. Comparison 1 Antidepressants versus placebo, Outcome 23 CRP at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 23 CRP at 12 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chojnacki 2011 30 6.99 (5.65) 30 9.4 (6.78) -2.41 [ -5.57, 0.75 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
Analysis 1.24. Comparison 1 Antidepressants versus placebo, Outcome 24 Cytokines TH Effector Memory
RA at 6 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 24 Cytokines TH Effector Memory RA at 6 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mikocka-Walus 2016c 14 45.8 (4.5) 12 39.7 (3.1) 6.10 [ 3.16, 9.04 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
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Analysis 1.25. Comparison 1 Antidepressants versus placebo, Outcome 25 Cytokines TC Effector Memory
RA at 6 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 25 Cytokines TC Effector Memory RA at 6 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mikocka-Walus 2016c 14 3.5 (0.48) 12 4.75 (0.9) -1.25 [ -1.82, -0.68 ]
-10 -5 0 5 10
Favours Antidepressants Favours Placebo
Analysis 1.26. Comparison 1 Antidepressants versus placebo, Outcome 26 Interleukin-10 at 6 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 26 Interleukin-10 at 6 months
Study or subgroup Antidepressants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mikocka-Walus 2016c 14 525.3 (93.2) 12 222.9 (63.2) 302.40 [ 241.89, 362.91 ]
-500 -250 0 250 500
Favours Antidepressants Favours Placebo
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Analysis 1.27. Comparison 1 Antidepressants versus placebo, Outcome 27 Need for steroids at 12 months.
Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
Comparison: 1 Antidepressants versus placebo
Outcome: 27 Need for steroids at 12 months
Study or subgroup Antidepressants Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goodhand 2012 0/29 1/29 0.33 [ 0.01, 7.86 ]
0.01 0.1 1 10 100
Favours Antidepressants Favours Placebo
A D D I T I O N A L T A B L E S
Table 1. Newcastle-Ottawa Scale results for observational study by Goodhand 2012
Case Con-
trol Study
Is the case
defi-
nition ade-
quate? (/1)
Represen-
tativeness
of the cases
(/1)
Selection
of controls
(/1)
Definition
of controls
(/1)
Compa-
rability of
cases and
controls on
the basis of
the design
or analysis
(/2)
Assess-
ment of ex-
posure (/1)
Same
method of
ascertain-
ment for
cases and
controls (/
1)
Non-
Response
Rate (/1)
Goodhand
(2012)
1 - 1 - 2 1 1 1 7
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. (Inflammatory bowel disease* or IBD).mp.
2. Exp Crohn disease/ or crohn*.mp.
3. Exp ulcerative colitis/ or (ulcerat* and colitis)
4. Exp enterocolitis/ or pancolitis/ or proctitis/ or proctocolitis/
5. 1 or 2 or 3 or 4
6. Exp antidepress*.mp or anti-depress*.mp or (anti depress*)
7. Exp MAO*.mp or (monoamine oxidase inhibit*).mp
8. Exp (serotonin or norepinephrine or noradrenaline or neurotransmitt* or dopamin*).mp or (uptake or reuptake or re-uptake or “re
uptake”).mp
9. Exp NARI*.mp or NDRI*.mp or SARI*.mp or SNRI*.mp or SSRI*.mp or tetracyclic*.mp or TCA*.mp or tricyclic*.mp or
pharmacotherap*.mp or psychotropic*.mp or (drug therapy).mp or thymoanaleptic*.mp or thymoleptic*.mp or atypical.mp
10. (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Beflox-
atone or Benactyzine or Bifemelane or Binospirone or Brofaromine or Bupropion or Amfebutamone or Butriptyline or Caroxa-
zone or Cianopramine or Cilobamine or Cimoxatone or Citalopram or Chlorimipramin* or Clomipramin* or Chlomipramin* or
Clomipramine or Clorgyline or Clovoxamine or CX157 or Tyrima or Demexiptiline or Deprenyl or Desipramin* or Pertofrane or
Desvenlafaxine or Dibenzepin or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine
or DVS-233 or Escitalopram or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or Gepirone or Imipramin* or
Iprindole or Iproniazid* or Iproclozide or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramin* or Lu AA21004* or Vor-
tioxetine or Lu AA24530* or LY2216684* or Edivoxetine or Maprotiline or medifoxamine or Melitracen or Metapramine or Mianserin
or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Nor-
fenfluramine or Nortriptylin* or Noxiptilin* or Opipramol or Oxaflozane or Oxitriptan or Paroxetine or Phenelzine or Pheniprazine
or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or
Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin*or Toloxatone or Tranylcypromin* or
Trazodone or Trimipramine or Tryptophan or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Vortioxetine or Zalospirone or
Zimeldine).mp
11. 6 or 7 or 8 or 9 or 10
12. 5 AND 11
Appendix 2. Embase search strategy
1. (Inflammatory bowel disease* or IBD).mp.
2. Exp Crohn disease/ or crohn*.mp.
3. Exp ulcerative colitis/ or (ulcerat* and colitis)
4. Exp enterocolitis/ or pancolitis/ or proctitis/ or proctocolitis/
5. 1 or 2 or 3 or 4
6. Exp antidepress*.mp or anti-depress*.mp or (anti depress*)
7. Exp MAO*.mp or (monoamine oxidase inhibit*).mp
8. Exp (serotonin or norepinephrine or noradrenaline or neurotransmitt* or dopamin*).mp or (uptake or reuptake or re-uptake or “re
uptake”).mp
9. Exp NARI*.mp or NDRI*.mp or SARI*.mp or SNRI*.mp or SSRI*.mp or tetracyclic*.mp or TCA*.mp or tricyclic*.mp or
pharmacotherap*.mp or psychotropic*.mp or (drug therapy).mp or thymoanaleptic*.mp or thymoleptic*.mp or atypical.mp
10. (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Beflox-
atone or Benactyzine or Bifemelane or Binospirone or Brofaromine or Bupropion or Amfebutamone or Butriptyline or Caroxa-
zone or Cianopramine or Cilobamine or Cimoxatone or Citalopram or Chlorimipramin* or Clomipramin* or Chlomipramin* or
Clomipramine or Clorgyline or Clovoxamine or CX157 or Tyrima or Demexiptiline or Deprenyl or Desipramin* or Pertofrane or
Desvenlafaxine or Dibenzepin or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine
or DVS-233 or Escitalopram or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or Gepirone or Imipramin* or
Iprindole or Iproniazid* or Iproclozide or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramin* or Lu AA21004* or Vor-
tioxetine or Lu AA24530* or LY2216684* or Edivoxetine or Maprotiline or medifoxamine or Melitracen or Metapramine or Mianserin
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or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Nor-
fenfluramine or Nortriptylin* or Noxiptilin* or Opipramol or Oxaflozane or Oxitriptan or Paroxetine or Phenelzine or Pheniprazine
or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or
Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin*or Toloxatone or Tranylcypromin* or
Trazodone or Trimipramine or Tryptophan or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Vortioxetine or Zalospirone or
Zimeldine).mp
11. 6 or 7 or 8 or 9 or 10
5 AND 11
Appendix 3. CINAHL search strategy
1. (TI inflammatory bowel or AB inflammatory bowel) OR (TI IBD or AB IBD) OR (TI Crohn* or AB Crohn*) OR (TI CD or AB
CD) OR (TI ulcerative colitis or AB ulcerative colitis) OR (TI colitis* or AB colitis*) OR (TI UC or AB UC) OR (TI enterocolitis or
AB enterocolitis) OR (TI pancolitis or AB pancolitis) OR (TI proctitis or AB proctitis) OR (TI proctocolitis or AB proctocolitis) OR
(TI ileitis or AB ileitis) OR (TI ileocolitis or AB ileocolitis) OR (TI enteritis or AB enteritis)
2. (TI antidepress* or AB antidepress*) OR (TI anti-depress* or AB anti-depress*) OR (TI anti depress* or AB anti depress*) OR
(TI MAO* or AB MAO*) OR (TI monoamine oxidase inhibit* or AB monoamine oxidase inhibit*) OR (TI serotonin* or AB
serotonin*) OR (TI norepinephrine or AB norepinephrine) OR (TI noradrenaline or AB noradrenaline) OR (TI neurotransmitt* or
AB neurotransmitt*) OR (TI dopamin* or AB dopamin*) OR (TI NARI* or AB NARI*) OR (TI NDRI* or AB NDRI*) OR (TI
SARI* or AB SARI*) OR (TI SNRI* or AB SNRI*) OR (TI SSRI* or AB SSRI*) OR (TI tetracyclic* or AB tetracyclic*) OR (TI
TCA* or AB TCA*) OR (TI tricyclic* or AB tricyclic*) OR (TI pharmacotherap* or AB pharmacotherap*) OR (TI psychotropic* or
AB psychotropic*) OR (TI drug therapy or AB drug therapy) OR (TI thymoanaleptic* or AB thymoanaleptic*) OR (TI thymoleptic*
or AB thymoleptic*) OR (TI atypical or AB atypical)
Appendix 4. PsycINFO search strategy
TI (Inflammatory bowelOR IBDORCrohn*ORulcerative colitisOR enterocolitisORpancolitisORproctitisORproctocolitis) AND
TI (antidepress* OR anti-depress* OR anti depress* OR MAO* OR monoamine oxidase inhibit* OR serotonin OR norepinephrine
OR noradrenaline OR neurotransmitt* OR dopamin* OR NARI* OR NDRI* OR SARI* OR SNRI* OR SSRI* OR tetracyclic* OR
TCA* OR tricyclic* OR pharmacotherap* OR psychotropic* OR drug therapy OR thymoanaleptic* OR thymoleptic* OR atypical)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The Primary and Tertiary outcomes were previously specified as “Changes in [a scale]...”, but after consideration, we decided to include
studies that report outcomes not only as changes, but also between group differences. The “Changes in [a scale]...” phrasing was omitted
to just listing the type of outcome and the type of scale, e.g. “Anxiety and depression as measured by any well-established anxiety or
depression scale”. Further, to this we reworded ’validated’ to ’well-established’. While well-established scales are usually validated, some
scales, such as the CDAI, are actually not appropriately validated while they are widely used and performs well in studies.
Further, following feedback from the editors and peer-reviewers, and to simplify data reporting, we reordered our outcome measures.
Efficacy, in terms of symptoms of anxiety and depression, was considered the primary outcome measure in the review. Safety - adverse
events and serious adverse events, study withdrawals due to adverse events, and other efficacy measures such as QoL, clinical remission,
relapse, pain, hospital admissions, surgery, need for steroid treatment were considered secondary outcome measures. Tertiary outcome
measures were moved under secondary outcome measures. Clinical remission and relapse were simplified - we have now removed the
comments regarding ’at completion’ and ’at follow-up’. We also reordered our objectives, with the assessment of anxiety and depression
being the primary objective, and the remaining objectives being secondary. We changed the word ’managing’ to ’treating’ for objective
1 and for ’improving’ for objective 2.
We decided to not run the search of The UK National Research Register as at the moment of the search it was considered an archived
site which was no longer updated. Instead we searched the EU clinical trials register.
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